Sam Brusco, Associate Editor06.15.22
Johnson & Johnson Vision has gained U.S. Food and Drug Administration (FDA) clearance, Health Canada approval, and CE mark approval for its new AcuVue Oasys Max 1-Day and AcuVue Oasys Max q-Day Multifocal contact lenses.
According to the company, the lenses help provide all-day comfort and visual clarity amid today’s modern lifestyles, long hours, and increased digital device use that take a toll on eye comfort.
A recent survey found 71% of eye care professionals see patients experiencing eye discomfort related to increased screen time—young contact lens wearers spend an average of nine hours a day in front of a screen. This causes them to blink less and have more dryness and eye fatigue.
“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” Peter Menziuso, company group chairman of Johnson & Johnson Vision told the press. As pioneers in eye health, we’re leading with high science and deep clinical expertise to innovate for those moments that matter. ACUVUE OASYS MAX 1-Day is the latest in our long heritage of leading-edge innovation and we look forward to bringing this solution for patients experiencing ever-demanding lifestyles and environments.”
The new contact lenses are available in spherical and multifocal configurations to address multiple vision correction needs. J&J Vision expects to launch them in the U.S., Canada, and multiple European countries in the fall.
According to the company, the lenses help provide all-day comfort and visual clarity amid today’s modern lifestyles, long hours, and increased digital device use that take a toll on eye comfort.
A recent survey found 71% of eye care professionals see patients experiencing eye discomfort related to increased screen time—young contact lens wearers spend an average of nine hours a day in front of a screen. This causes them to blink less and have more dryness and eye fatigue.
“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” Peter Menziuso, company group chairman of Johnson & Johnson Vision told the press. As pioneers in eye health, we’re leading with high science and deep clinical expertise to innovate for those moments that matter. ACUVUE OASYS MAX 1-Day is the latest in our long heritage of leading-edge innovation and we look forward to bringing this solution for patients experiencing ever-demanding lifestyles and environments.”
The new contact lenses are available in spherical and multifocal configurations to address multiple vision correction needs. J&J Vision expects to launch them in the U.S., Canada, and multiple European countries in the fall.
